肉碱复方制剂对急性冠脉综合征缺血心肌的影响

目的：观察肉碱复方制剂对急性冠脉综合征（ACS）患者氧自由基的影响，评价该制剂在ACS治疗中的临床价值。方法：急性冠脉综合征患者共40例，随机分为治疗组（A组，20例），口服肉碱复方制剂10 mL，每日2次，连续30 d,余同B组;对照组（B组，20例）常规治疗;C组为正常献血者。测定A、B两组治疗前后血清SOD、MDA含量等相关指标。结果：血清SOD：A组治疗前和B组治疗前后均低于C组(P<0.01)，A组治疗后与C组比较差异无显著性；治疗前A、B组差异无显著性(P>0.05)，治疗后A组高于B组；A组治疗后高于治疗前(P<0.01)，B组治疗前后无变化。血清MDA：A和B组治疗前后均高于C组(P<0.01)；治疗前和治疗后A和B组比较差异无显著性(P>0.05)；A和B组治疗后低于治疗前(P<0.01)，但仍于高C组。结论:肉碱复方制剂可以减轻氧自由基的损伤作用，保护急性冠脉综合征患者缺血心肌。

Effects of carnitine pharceutics on ischemic myocardium in acute coronary syndrome

Objective To observe the effects of complex pharmaceutics containing carnitine and eortcd on oxygen free radical (OFR) activity in acute coronary syndrome (ACS) patients. Methods Forty patients with ACS were divided into two groups randomly:carnitine and eortcd therapy group (A group, 20 cases) and routine therapy group (B group ,20 cases). 20 healthy blood donors were served as control (C group).Patients in A group were given carnitine and eortcd 10 mL ,bid p o., twice a day for 30 days, and other administrations were the same as B group. The levels of serum SOD and MDA in A and B group before and after therapy were detected.Results The levels of serum SOD in A group before therapy and B group before and after therapy were lower than that in C group ( P <0 01),there was no diffence between A group after therapy and C group, as well as A and B group before therapy ( P >0 05) . After therapy, A group was higher than B group. The concentration of MDA in A and B groups were higher than that in C group ( P <0 01).The level of serum SOD in A group increased significantly after therapy ( P <0 05), there was no significant difference in B group before and after therapy ( P <0 05); the MDA in A and B groups decreased markedly after therapy, compared with C group ( P >0 01), before and after therapy, there was no significant difference between A and B group ( P >0 05). The levels of serum MDA after therapy in A and B group were lower than before therapy ( P <0 01), however, they were higher than C group. Conclusion Canitine and eortcd can alleviate the injury of OFR and has protective function on ischemic myocardium in ACS patients.